Latest Global Markets News

Tivan Limited has submitted a confidential draft Feasibility Study for its Speewah Fluorite Project to key partners, marking a significant step towards project finalisation and potential production.

Argo Global Listed Infrastructure Limited has reported a sharp 72% decline in half-year profit for the period ending December 2025, driven by unrealised fair value losses on its investment portfolio. Despite this, the company has declared a higher fully franked interim dividend of 4.5 cents per share.

Citigroup Global Markets Australia has announced the record and ex-dividend dates for a fully franked dividend on MFG ordinary shares and its linked CitiFirst Self-Funding Instalment MINI, with dividends directed to reduce outstanding loan amounts.

London City Equities Limited reported a 38% revenue increase and a $5.6 million capital gain from asset sales, while boosting liquidity to nearly 60% of its portfolio and raising dividends amid a cautious investment outlook.

Diversified United Investment Limited reported a modest profit increase for the half year ending December 2025, alongside a stable dividend and a proposed merger with Australian United Investment Company Limited.

Charter Hall Group has reported a strong first half for FY26, with operating earnings surging 21.6% and record equity inflows driving funds under management to $92.2 billion. The group has upgraded its full-year earnings guidance, signalling confidence amid ongoing market volatility.

Evion Group has secured formal notice from Madagascar’s Mines Ministry that its Maniry Graphite Project permits have passed technical assessment and are set for expedited approval, marking a key step towards production.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

Hearts and Minds Investments Limited reported a dramatic 97% drop in half-year comprehensive income to $3 million, with a largely flat investment portfolio and a significant write-down of Corporate Travel Management shares. Despite this, the company declared a fully franked interim dividend of 9.5 cents per share.

Telix Pharmaceuticals has lodged a European marketing authorization application for TLX101-Px, a novel PET imaging agent targeting glioma brain cancer, aiming to enhance diagnostic precision and patient access across major European markets.

Citigroup Global Markets Australia has announced key dividend dates for CBA CitiFirst Self-Funding Instalment MINIs, aligning with Commonwealth Bank ordinary shares and adjusting outstanding loan amounts for holders.

Morphic Ethical Equities Fund Limited reported a half-year profit after tax of $1.26 million for December 2025, declaring a fully franked 1 cent dividend and continuing its share buy-back program.